Treatment of acute lymphoblastic leukemia in older adults: Now and the future

Clinical Advances in Hematology and Oncology

Volumn 15, Issue 4, 2017, Pages 266-274

  Yilmaz, Musa ^a   Kantarjian, Hagop ^a   Jabbour, Elias ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Blinatumomab; Inotuzumab ozogamicin; Older adults; Tyrosine kinase inhibitors

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; BLINATUMOMAB; BOSUTINIB; CORTICOSTEROID; CYTARABINE; CYTOCHROME P450; DASATINIB; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; HYPERICUM PERFORATUM EXTRACT; INOTUZUMAB OZOGAMICIN; MITOXANTRONE; NILOTINIB; NON PRESCRIPTION DRUG; PONATINIB; PRESCRIPTION DRUG; PROTEIN TYROSINE KINASE INHIBITOR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FRAIL ELDERLY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; LIVER TOXICITY; MORTALITY RATE; MULTICENTER STUDY (TOPIC); MYELOID LEUKEMIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYPHARMACY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; AGE; AGED; DISEASE MANAGEMENT; MORTALITY; MULTIMODALITY CANCER THERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 85019056984     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. SEER stat fact sheets: acute lymphocytic leukemia (ALL). National Cancer Institute. http://seer.cancer.gov/statfacts/html/alyl.html. Updated September 12, 2016. Accessed February 23, 2017.
2. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-2765.
3. Thomas X, Olteanu N, Charrin C, Lhéritier V, Magaud JP, Fiere D. Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol. 2001;67(2):73-83.
4. Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115(2):206-214.
5. Gökbuget N, Hartog MC, Dengler J. First analysis of prognostic factors in elderly Ph/BCR-ABL negative ALL including comorbidity scores: different factors predict mortality and relapse [Joint Meeting of the German, Austrian and Swiss Societies for Hematology and Oncology abstract V29]. Onkologie. 2008;31(suppl 4):14.
6. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104(9):1998-2005.
7. Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older adults. Br J Cancer. 2008;98(3):517-522.
8. Rubin EH, Andersen JW, Berg DT, Schiffer CA, Mayer RJ, Stone RM. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol. 1992;10(6):948-953.
9. Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol. 2003;51(5):395-402.
10. Cusack BJ, Young SP, Vestal RE, Olson RD. Age-related pharmacokinetics of daunorubicin and daunorubicinol following intravenous bolus daunorubicin administration in the rat. Cancer Chemother Pharmacol. 1997;39(6):505-512.
11. Kim IH, Kisseleva T, Brenner DA. Aging and liver disease. Curr Opin Gastroenterol. 2015;31(3):184-191.
12. Ippoliti C, Patel M. A retrospective chart review on the toxicity of pegylated asparaginase in adult patients with acute lymphoblastic leukemia. J Hematol Oncol Pharm. 2014;4(2):42-48.
13. Fathi AT, DeAngelo DJ, Stevenson KE, et al. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016;122(15):2379-2388.
14. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648-1671.
15. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94(3):1086-1099.
16. Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12(13):1249-1257.
17. Puts MT, Monette J, Girre V, et al. Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study. Drugs Aging. 2010;27(7):559-572.
18. Larson RA. Acute lymphoblastic leukemia: older patients and newer drugs. Hematology Am Soc Hematol Educ Program. 2005;1:131-136.
19. O’Brien S, Thomas DA, Ravandi F, Faderl S, Pierce S, Kantarjian H. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113(8):2097-2101.
20. Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098-1107.
21. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974-977.
22. Löffler A, Gruen M, Wuchter C, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/ anti-CD3 single-chain antibody construct. Leukemia. 2003;17(5):900-909.
23. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57-66.
24. Topp MS. Blinatumomab improved overall survival in patients with relapsed or refractory philedelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (TOWER) [EHA abstract S149]. Haematologica. 2016;101(suppl 1).
25. Topp MS, Zimmerman Z, Cannell P, et al. Health-related quality of life (HRQoL) of blinatumomab versus standard of care (SOC) chemotherapy in patients with relaspsed or refractory Philadelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (TOWER) [ASH abstract 222]. Blood. 2016;128(22)(suppl).
26. Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134-4140.
27. Kantarjian HM, Stein AS, Bargou RC, et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies. Cancer. 2016;122(14):2178-2185.
28. Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol. 2015;6(5):253-261.
29. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403-411.
30. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15):2728-2736.
31. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740-753.
32. Sasaki K, Jabbour EJ, O’Brien SM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia (ALL): interim result of a phase II clinical trial. [ASH abstract 588]. Blood. 2016;128(22)(suppl).
33. Rousselot P, Coudé MM, Gokbuget N, et al; European Working Group on Adult ALL (EWALL) group. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128(6):774-782.
34. Chiaretti S, Vitale A, Elia L, et al. Multicenter total therapy Gimema LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic-based prognostic stratification [ASH abstract 81]. Blood. 2015;126(23)(suppl).
35. Sasaki K, Jabbour E, Ravandi F, et al. Phase II study of the frontline hyper-CVAD in combination with ponatinib for patients with Philadelphia chromosome positive acute lymphoblastic leukemia. [ASH abstract 757]. Blood. 2016;128(22) (suppl).
36. Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84-91.
37. Dhédin N, Huynh A, Maury S, et al; GRAALL group. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125(16):2486-2496.
38. Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595-1604.
39. Martino R, Giralt S, Caballero MD, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. Haematologica. 2003;88(5):555-560.
40. Hamaki T, Kami M, Kanda Y, et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. Bone Marrow Transplant. 2005;35(6):549-556.
41. Mohty M, Labopin M, Volin L, et al; Acute Leukemia Working Party of EBMT. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2010;116(22):4439-4443.
42. Marks DI, Wang T, Pérez WS, et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010;116(3):366-374.
43. Ram R, Storb R, Sandmaier BM, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica. 2011;96(8):1113-1120.
44. Arnold R, Massenkeil G, Bornhäuser M, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia. 2002;16(12):2423-2428.
45. Seftel MD, Neuberg D, Zhang MJ, et al; Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016;91(3):322-329.
46. Petersdorf SH, Kopecky KJ, Head DR, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrex-ate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia. 2001;15(2):208-216.
47. Annino L, Vegna ML, Camera A, et al; GIMEMA Group. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99(3):863-871.
48. Kantarjian HM, O’Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547-561.
49. Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ ECOG2993 trial. Br J Haematol. 2012;157(4):463-471.
50. Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111(5):2563-2572.
51. Sancho JM, Ribera JM, Xicoy B, et al; PETHEMA Group. Results of the PET-HEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2007;78(2):102-110.
52. Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109(9):3676-3678.
53. Delannoy A, Delabesse E, Lhéritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Phil-adelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia. 2006;20(9):1526-1532.
54. Ottmann OG, Wassmann B, Pfeifer H, et al; GMALL Study Group. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer. 2007;109(10):2068-2076.